MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company’s products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
तुलना करने के लिए मीट्रिक्स | MEDCL | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधMEDCLपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −19.5x | 10.2x | −0.7x | |
PEG अनुपात | −0.63 | 0.04 | 0.00 | |
क़ीमत/बुक | −11.9x | 2.2x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 40.8x | 2.2x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 35.7% | 54.4% | 47.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 18.1% | 7.5% | अनलॉक करें |